Most Recent
Construction giant Lendlease faces a second shareholder class action over market disclosures relating to its underperforming engineering division, and joining the case is one of the biggest public pension funds in the US.
Law firm HWL Ebsworth is due in court Wednesday for a hearing in its challenge to a judgment awarding an expelled partner $450,000 in damages for his "irrational and wrong" dismissal.
A catfight has broken out between construction equipment and workwear maker Caterpillar and sneaker giant Puma, with Caterpillar arguing Puma's 'procat' trade mark is deceptively similar to its 'cat' marks.
Insolvency firm Kordamentha has filed proceedings against ten former directors of the Arrium Group, accusing them of breaching of their duties to prevent insolvent trading after the steel giant collapsed with almost $4 billion in debt.
Defence shipbuilder Austal faces legal action by the corporate regulator challenging claims of privilege over documents sought as part of a probe into disclosures linked to cost overruns on the company's $4 billion US Navy ship-building program.
The settlement of the Discovery Metals investor class action against KPMG has experienced another setback, after scheme administrator Grant Thornton flagged a potential conflict of interest in acting as a costs contradictor over Piper Alderman’s controversial $3.5 million legal bill.
A judge who this month faced strong criticism from an appeals court for his "egregious" conduct in a case, has stepped down from senior administrative roles on the Federal Circuit Court and will receive mentoring, the court confirmed Monday.
Mylan has launched a lawsuit against Cipla for allegedly copying the get-up of its blockbuster cholesterol drug Lipidil, after losing a bid to block Cipla and Sun Pharma from selling generic versions of the drug while it appeals a ruling invalidating several claims of its patents.
Patents at the centre of a high stakes IP dispute between tech giants Motorola and Hytera have significantly more than the necessary “scintilla of inventiveness” to be deemed valid, Motorola said on the first day of a month-long trial.
A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company's lawyers sent an email with the wrong opposition deadline.